Vincerx Pharma (Vincerx Pharma) Debt-to-Equity : -3.57 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Debt-to-Equity?

Vincerx Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.20 Mil. Vincerx Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.02 Mil. Vincerx Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-0.62 Mil. Vincerx Pharma's debt to equity for the quarter that ended in Mar. 2024 was -3.57.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vincerx Pharma's Debt-to-Equity or its related term are showing as below:

VINC' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.57 Med: 0.06 Max: 0.22
Current: -3.57

During the past 5 years, the highest Debt-to-Equity Ratio of Vincerx Pharma was 0.22. The lowest was -3.57. And the median was 0.06.

VINC's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs VINC: -3.57

Vincerx Pharma Debt-to-Equity Historical Data

The historical data trend for Vincerx Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Debt-to-Equity Chart

Vincerx Pharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.04

0.07

0.22

Vincerx Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												0.10	0.13	0.18	0.22	-3.57

Competitive Comparison of Vincerx Pharma's Debt-to-Equity

For the Biotechnology subindustry, Vincerx Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vincerx Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vincerx Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vincerx Pharma's Debt-to-Equity falls into.

Vincerx Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vincerx Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.162	+	1.34)	/	11.222
	=	0.22

Vincerx Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.198	+	1.021)	/	-0.622
	=	-3.57

Vincerx Pharma (NAS:VINC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vincerx Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vincerx Pharma (Vincerx Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (NAS:VINC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

260 Sheridan Avenue, Suite 400, Palo Alto, CA, USA, 94306

Website

https://www.vincerx.com

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.

Executives

Alexander A. Seelenberger	officer: Chief Financial Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi	director, 10 percent owner, officer: Chief Operations Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy	director, 10 percent owner, officer: President and CEO	995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas	officer: See Remarks	180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe	director	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang	officer: Chief Business Officer	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang	officer: Chief Technology Officer	260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens	director	260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus	officer: Chief Medical Officer	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd	10 percent owner	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee	director	4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054